UBS lowered the firm’s price target on Surgery Partners (SGRY) to $29 from $34 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners Appoints New COO and President
- Strategic Growth and Portfolio Optimization Drive Buy Rating for Surgery Partners
- Surgery Partners price target lowered to $31 from $35 at RBC Capital
- Surgery Partners price target lowered to $30 from $35 at Benchmark
- Surgery Partners Reports Q3 2025 Financial Results